HEMOSATE ULTRA HS2150 263 G
SODIUM CHLORIDE : 263 G POTASSIUM CHLORIDE : 6.71 G CALCIUM CHLORIDE : 7.47 G SODIUM ACETATE : 1.11 G DEXTROSE : 49.5 G CITRIC ACID : 6.91 G MAGNESIUM CHLORIDE : 2.14 G · DIN 02413957 · CHIEF MEDICAL SUPPLIES LTD
Health Canada status: DORMANT
What is HEMOSATE ULTRA HS2150?
HEMOSATE ULTRA HS2150 263 G contains SODIUM CHLORIDE : 263 G POTASSIUM CHLORIDE : 6.71 G CALCIUM CHLORIDE : 7.47 G SODIUM ACETATE : 1.11 G DEXTROSE : 49.5 G CITRIC ACID : 6.91 G MAGNESIUM CHLORIDE : 2.14 G. It is listed in the Health Canada Drug Product Database under DIN 02413957, held by CHIEF MEDICAL SUPPLIES LTD, supplied as SOLUTION for HAEMODIALYSIS administration. Health Canada currently lists it as dormant, status dated 02-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HEMOSATE ULTRA HS2150 used for?
Acid component of a two-component mixture used for hemodialysis treatment for patients suffering from renal insufficiency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02413957 |
|---|---|
| Brand name | HEMOSATE ULTRA HS2150 |
| Generic / active ingredient | SODIUM CHLORIDE : 263 G POTASSIUM CHLORIDE : 6.71 G CALCIUM CHLORIDE : 7.47 G SODIUM ACETATE : 1.11 G DEXTROSE : 49.5 G CITRIC ACID : 6.91 G MAGNESIUM CHLORIDE : 2.14 G |
| Manufacturer | CHIEF MEDICAL SUPPLIES LTD |
| Strength | 263 G |
| Dosage form | SOLUTION |
| Route of administration | HAEMODIALYSIS |
| Schedule | Ethical |
| ATC code | B05ZA HEMODIALYTICS, CONCENTRATES |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 02-Jul-2025 |
| Original market date | 2015-01-08 00:00:00 |
How is it administered?
Administered via three-stream hemodialysis machine. Dilute 1 part acid concentrate with 1.72 parts bicarbonate solution and 42.28 parts purified water USP. Approx 2.7 L required for 5 hours treatment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15 - 30°C). Do not freeze.
How is it supplied?
4.5 L and 5 L polyethylene containers.
Contraindications
Hypersensitivity to this drug or any component of the container; for injection or peritoneal dialysis.
Warnings and precautions
For hemodialysis use only. Do not use for injection or peritoneal dialysis. Must be used with concentrated Bicarbonate Solution. Do not use if precipitate is present or container is damaged.
What can be used instead?
Other Canadian products sharing ATC code B05ZA HEMODIALYTICS, CONCENTRATES. 117 of 588 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACID CONCENTRATE 2156 | 10.1 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02239491 |
| ACID CONCENTRATE 2182 | 262.98 G | SOLUTION | VANTIVE ULC | MARKETED | DIN 02210835 |
| ACID CONCENTRATE A1221 | 3.35 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254344 |
| ACID CONCENTRATE A1222 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254336 |
| ACID CONCENTRATE A1223 | 9.92 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254328 |
| ACID CONCENTRATE A1224 | 263 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254301 |
| ACID CONCENTRATE A1225 | 263.0 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254298 |
| ACID CONCENTRATE A1226 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254255 |
| ACID CONCENTRATE A1227 | 8.27 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02254247 |
| ACID CONCENTRATE A1228 | 49.5 G | SOLUTION | CHIEF MEDICAL SUPPLIES LTD | MARKETED | DIN 02533774 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.